Jeffrey C Goh

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemoth...

The Lancet. Oncology · 2026-01

Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCG...

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 september 2025

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resista...

The Lancet. Oncology · 2025-09

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3,...

European journal of cancer (Oxford, England : 1990) · 25 juli 2025

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastati...

The Lancet. Oncology · 2025-03

Cemiplimab in recurrent cervical cancer: Final analysis of totale overleving in the phase III EMPOWER-Cervical 1/GOG-...

European journal of cancer (Oxford, England : 1990) · 5 februari 2025

Adjuvant nivolumab bij gelokaliseerd hoogrisico RCC na nefrectomie: CheckMate 914 part B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 januari 2025

Lu-PSMA-617 plus enzalutamide bij mCRPC: PSMAfore fase III

The Lancet. Oncology · 2024-05

Lenvatinib plus pembrolizumab versus sunitinib bij mRCC: CLEAR definitieve OS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024

OS met Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP definitieve OS

The Lancet. Oncology · 2024-01

Pembrolizumab plus olaparib bij biomarker-ongeselecteerd mCRPC: KEYLYNK-010 fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 augustus 2023

Adjuvant nivolumab plus ipilimumab versus placebo na nefrectomie bij RCC: CheckMate 914 fase III

Lancet (London, England) · 11 maart 2023

Lenvatinib plus pembrolizumab versus sunitinib bij mRCC: CLEAR langetermijn

The Lancet. Oncology · 2023-03

QoL bij mRCC onder lenvatinib-pembrolizumab: CLEAR analyse

The Lancet. Oncology · 2022-06

Lenvatinib plus pembrolizumab of everolimus bij gevorderd RCC: CLEAR/KEYNOTE-581 fase III

The New England journal of medicine · 8 april 2021

Nivolumab plus cabozantinib versus sunitinib bij gevorderd RCC: CheckMate 9ER fase III

The New England journal of medicine · 4 maart 2021

[177Lu]Lu-PSMA-617 versus cabazitaxel bij mCRPC: TheraP fase II

Lancet (London, England) · 27 februari 2021

Bevacizumab plus platina-chemotherapie bij recidief ovariumcarcinoom: MITO-16B definitief

The Lancet. Oncology · 2020-05

Rucaparib-onderhoud bij recidief ovariumcarcinoom na platinarespons: ARIEL3 fase III-studie

Lancet (London, England) · 28 oktober 2017